Indivior Pharmaceuticals (INDV) Receivables - Net (2021 - 2026)
Indivior Pharmaceuticals (INDV) posted quarterly Receivables - Net of $273.0 million for Q1 2026, up 12.35% year-over-year from $243.0 million in Q1 2025, and up 7.91% quarter-over-quarter from $253.0 million in Q4 2025.
Indivior Pharmaceuticals (INDV) Receivables - Net (2021 - 2026) Analysis & Trends
Indivior Pharmaceuticals' Receivables - Net history runs 6 years deep, the most recent figure standing at $273.0 million for Q1 2026.
- In Q1 2026, Receivables - Net rose 12.35% year-over-year to $273.0 million; the TTM figure through Mar 2026 stood at $273.0 million (up 12.35% YoY), while the FY2025 annual figure was $253.0 million, changed 0.39% from the prior year.
- Receivables - Net for Q1 2026 stood at $273.0 million, up from $253.0 million in the prior quarter.
- The five-year high for Receivables - Net was $273.0 million in Q1 2026, with the low at $220.0 million in Q4 2022.
- The 5-year median for Receivables - Net is $253.5 million (2023), against an average of $249.5 million.
- The sharpest annual moves came in 2023 and 2025: Receivables - Net grew 15.45% in 2023, then fell 0.39% in 2025.
- Indivior Pharmaceuticals' Receivables - Net stood at $220.0 million in 2022, then advanced by 15.45% to $254.0 million in 2023, then changed by 0.0% to $254.0 million in 2024, then slipped by 0.39% to $253.0 million in 2025, then rose by 7.91% to $273.0 million in 2026.
- Business Quant data shows INDV's Receivables - Net at $273.0 million in Q1 2026, $253.0 million in Q4 2025, and $259.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - |
| 10 | Indivior Pharmaceuticals | 4.54 Bn | 4.31 Bn | 294.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 271.00 Mn |
| Jun 30, 2026 | 271.00 Mn |
| Mar 31, 2026 | 273.00 Mn |
| Mar 31, 2026 | 273.00 Mn |
| Dec 31, 2025 | 253.00 Mn |
| Dec 31, 2025 | 253.00 Mn |
| Sep 30, 2025 | 259.00 Mn |
| Sep 30, 2025 | 259.00 Mn |
| Jun 30, 2025 | 240.00 Mn |
| Jun 30, 2025 | 240.00 Mn |
| Mar 31, 2025 | 243.00 Mn |
| Mar 31, 2025 | 243.00 Mn |
| Dec 31, 2024 | 254.00 Mn |
| Dec 31, 2024 | 254.00 Mn |
| Dec 31, 2023 | 254.00 Mn |
| Dec 31, 2023 | 254.00 Mn |
| Dec 31, 2022 | 220.00 Mn |
| Dec 31, 2022 | 220.00 Mn |
| Dec 31, 2021 | 202.00 Mn |
| Dec 31, 2021 | 202.00 Mn |